InnoSer participates in the AACR annual meeting 2020

InnoSer participates in the AACR annual meeting 2020

InnoSer is proud to announce its participation in the annual meeting of the American Association for Cancer Research. As committed contributors to the preclinical oncology field, we look forward to interacting with the community throughout the event. We make this...
InnoSer joins the Eurostars funded project ‘LEMONAID’

InnoSer joins the Eurostars funded project ‘LEMONAID’

LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...
InnoSer meets you at knowledge for growth event

InnoSer meets you at knowledge for growth event

[EDIT]: This event is now hold digitally, and we are looking forward to talking to you at one of our virtual meetings. Detailed schedules to be announced soon! Organized by flanders.bio since it’s establishment in 2004, knowledge for growth brings over 1300...
InnoSer welcomes Wim Tiest as its Chief Technology Officer

InnoSer welcomes Wim Tiest as its Chief Technology Officer

As of April 2020, Wim Tiest has joined InnoSer in the role of Chief Technology Officer (CTO) and as part of the company management team. Wim holds a MSc in biochemical engineering and in artificial intelligence, both from the KU Leuven. He has built his professional...
PDX/O oncology platform developments at InnoSer

PDX/O oncology platform developments at InnoSer

Despite the challenging times for the life sciences sector during coronavirus restrictions, we’ve been fortunate enough and well prepared to continue with the development of our PDX/O platform for oncology research. On a weekly basis we receive patient tumor samples...